Evidence map›Paper›PMID 21818257›Full record

SynthesisPloS one2011

Molecular sub-classification of renal epithelial tumors using meta-analysis of gene expression microarrays.

Thomas Sanford, Paul H Chung, Ariel Reinish, Vladimir Valera, Ramaprasad Srinivasan, W Marston Linehan, Gennady Bratslavsky

Abstract readMeta-Analysis
In one paragraph

Synthesis in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Thomas SanfordUrologic Oncology Branch, National Cancer Institute, Bethesda, Maryland, United States of America.
Paul H Chung
Ariel Reinish
Vladimir Valera
Ramaprasad Srinivasan
W Marston Linehan
Gennady Bratslavsky

Funding

Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase GeneZIABC011038 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$29.8M
Molecular Therapeutics of Kidney Cancer: MET Gene and BHD GeneZIABC011043 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$20.9M
Clinical Studies of the Molecular Genetic Basis of Kidney CancerZIABC011028 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.9M
Clinical Nursing and Data Management CoreZIDBC011089 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.4M
Molecular Therapeutics of Kidney Cancer: MET Gene and BHD GeneZ01BC011043 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2008 to 2008
$1.4M
Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase GeneZ01BC011038 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2008 to 2008
$1.4M
Clinical Studies of the Molecular Genetic Basis of Kidney CancerZ01BC011028 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2008 to 2008
$1.4M
Clinical Fellowship Training ProgramZ01BC011023 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PINTO, PETER · 2008 to 2008
$232k
Intramural NIH HHS Z01 BC011023Intramural NIH HHS Z01 BC011028Intramural NIH HHS Z01 BC011038Intramural NIH HHS Z01 BC011043
6 · The paper itself

Abstract

purposeTo evaluate the accuracy of the sub-classification of renal cortical neoplasms using molecular signatures. EXPERIMENTAL

designA search of publicly available databases was performed to identify microarray datasets with multiple histologic sub-types of renal cortical neoplasms. Meta-analytic techniques were utilized to identify differentially expressed genes for each histologic subtype. The lists of genes obtained from the meta-analysis were used to create predictive signatures through the use of a pair-based method. These signatures were organized into an algorithm to sub-classify renal neoplasms. The use of these signatures according to our algorithm was validated on several independent datasets.

resultsWe identified three Gene Expression Omnibus datasets that fit our criteria to develop a training set. All of the datasets in our study utilized the Affymetrix platform. The final training dataset included 149 samples represented by the four most common histologic subtypes of renal cortical neoplasms: 69 clear cell, 41 papillary, 16 chromophobe, and 23 oncocytomas. When validation of our signatures was performed on external datasets, we were able to correctly classify 68 of the 72 samples (94%). The correct classification by subtype was 19/20 (95%) for clear cell, 14/14 (100%) for papillary, 17/19 (89%) for chromophobe, 18/19 (95%) for oncocytomas.

conclusionsThrough the use of meta-analytic techniques, we were able to create an algorithm that sub-classified renal neoplasms on a molecular level with 94% accuracy across multiple independent datasets. This algorithm may aid in selecting molecular therapies and may improve the accuracy of subtyping of renal cortical tumors.

Indexed as

Gene Expression Regulation, NeoplasticAlgorithmsCluster AnalysisDatabases, GeneticGene Expression ProfilingHumansKidney NeoplasmsNeoplasms, Glandular and EpithelialOligonucleotide Array Sequence AnalysisReference StandardsReproducibility of Results

Identifiers

PMID21818257
PMCPMC3144884

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.